Skip to Main Content

The Pharmalot View

Latest

The Pharmalot View Ed Silverman

STAT Plus: Was Amgen less than forthcoming about FDA’s concerns on its cancer drug?

The Pharmalot View Ed Silverman

STAT Plus: Why the drug industry’s opaque warnings on price negotiations fall short

The Pharmalot View Ed Silverman

STAT Plus: Why a tone-deaf Regeneron executive deserved to be booed over Alzheimer’s drug remarks

The Pharmalot View Ed Silverman

STAT Plus: ‘Window dressing’: Eli Lilly’s after-the-fact statement on Indiana’s abortion law sends a disingenuous message

The Pharmalot View Ed Silverman

STAT Plus: ‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval

The Pharmalot View Ed Silverman

STAT Plus: When should drugmakers go all in and cut off essential medicines to Russia?

The Pharmalot View Ed Silverman

STAT Plus: If the Biogen CEO were truly ‘courageous,’ he would live with the Medicare decision

The Pharmalot View Ed Silverman

STAT Plus: Take a deep breath: Asthma drug study failed to include Black and Puerto Rican children who could benefit most

All Coverage

The Pharmalot View Ed Silverman

STAT Plus: Biden wants to bolster the pharma supply chain. A major generic plant closing may make that harder

The Pharmalot View Ed Silverman

STAT Plus: Too close for comfort: FDA shouldn’t loosen conflict rules for its expert panels

advertisement

The Pharmalot View Ed Silverman

By looking the other way, pharma money helped fuel a toxic political atmosphere in the U.S.

The Pharmalot View Ed Silverman

Oh, the irony! Trump may like to vilify drug makers, but now he needs them more than ever

The Pharmalot View Ed Silverman

‘Everyone was left to guess what went wrong’: An open letter to AstraZeneca’s CEO on transparency

The Pharmalot View Ed Silverman

Pharma drew a line in the sand over Covid-19 vaccine readiness — because someone had to

The Pharmalot View Ed Silverman

FDA commissioner needs to push back and tell Trump the agency is not part of the ‘deep state’

The Pharmalot View Ed Silverman

STAT Plus: Operation Warp Speed doesn’t have the transparency it needs

The Pharmalot View Ed Silverman

Where’s the data? In a pandemic, now is no time to sit on Covid-19 trial results

The Pharmalot View Ed Silverman

STAT Plus: We shouldn’t rush to use an unproven malaria drug to treat the coronavirus

The Pharmalot View Ed Silverman

Azar has a ‘tin ear’ when it comes to pricing a potential coronavirus treatment

The Pharmalot View Ed Silverman

STAT Plus: The FDA commissioner sweepstakes: Is Azar yearning to get out of Gottlieb’s shadow?

The Pharmalot View Ed Silverman

STAT Plus: Memo to the Novartis CEO: When in doubt, give the FDA a heads-up

The Pharmalot View Ed Silverman

STAT Plus: Trump proposes importing medicines, but he’s really seeking a quick political hit

The Pharmalot View Ed Silverman

STAT Plus: Grandstanding, not real change: Why drug prices in TV ads will be confusing and irrelevant

The Pharmalot View Ed Silverman

STAT Plus: Kapoor certainly deserves to go to jail, but so do some other pharma execs

The Pharmalot View Ed Silverman

STAT Plus: If the states don’t treat pharma as a utility, it may be ‘lights out’ for too many patients

The Pharmalot View Ed Silverman

STAT Plus: Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain

The Pharmalot View Ed Silverman

STAT Plus: Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator

The Pharmalot View Ed Silverman

STAT Plus: Prepare for grilling: 7 questions for 7 pharma execs who’ll testify before Congress about prices

The Pharmalot View Ed Silverman

STAT Plus: The list price is not right: Trump’s plan to force pharma to advertise prices is misguided